Liquidia Corporation
LQDA
株式のランク
#4413
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
株価
$38.75
最終同期: 2026-10-21
時価総額
$3.47B
変化（1日）
6.60%
変化（1年）
73.46%
国
US
取引 Liquidia Corporation (LQDA)
カテゴリー
Healthcare
Liquidia Corporation（LQDA）の株価履歴
終値の最高値: $30.60 （2026-10-01）
終値の最安値: $11.01 （2018-07-01）
終値の最安値: $11.01 （2018-07-01）
Liquidia Corporation の株価履歴（2018 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 42.98% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $45.29 | 34.87% |
SE
|
|
| $170.92 | 23.58% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
